Join Skye Bioscience for a virtual KOL Event featuring Louis J. Aronne, MD, FACP (Weill Cornell Medicine), Marcus DaSilva Goncalves, MD, PhD (NYU Langone Health), Lee M. Kaplan, MD, PhD (Geisel School of Medicine at Dartmouth), and Beverly Tchang, MD (Weill Cornell Medicine), who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism.

The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024.

A question and answer session will follow the formal presentations.